Opportunity Information: Apply for CDC RFA OE15 150302CONT16
Apply for CDC RFA OE15 150302CONT16
- The HHS-CDC in the health sector is offering a public funding opportunity titled "Reduction of Hemolysis in Specimens from Patients in Emergency Departments: Evaluation of Laboratory Medicine Best Practices and Recommendations" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.064.
- This funding opportunity was created on Feb 17, 2016 and posted on Feb 17, 2016.
- Applicants must submit their applications by Apr 15, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, titled "Reduction of Hemolysis in Specimens from Patients in Emergency Departments: Evaluation of Laboratory Medicine Best Practices and Recommendations," is a CDC cooperative agreement intended to support work focused on lowering hemolysis rates in blood specimens collected from patients in emergency departments (EDs). Hemolysis, the rupture of red blood cells during or after collection, can compromise lab results, trigger specimen rejection, and lead to redraws, delays in care, and increased costs. The emphasis of the opportunity is on evaluating laboratory medicine best practices and translating findings into practical recommendations that can be adopted in ED settings to improve specimen quality and reliability of testing.
The opportunity is issued by the U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), under Funding Opportunity Number "CDC RFA OE15 150302CONT16." It is categorized as a continuation opportunity and uses a cooperative agreement as the funding instrument, meaning the CDC is expected to have substantial involvement in the funded activities rather than acting only as a pass-through funder. The activity category is health, and the associated CFDA (Catalog of Federal Domestic Assistance) number is 93.064, which corresponds to CDC public health-related assistance programs.
The timeline in the source data indicates the announcement was created and posted on February 17, 2016, with an application closing date of April 15, 2016 (the original and current closing dates are the same). The listing notes an award ceiling of 0 and does not specify the expected number of awards, which typically suggests that the specific funding amount and/or number of awards may be defined elsewhere in the full announcement, negotiated under continuation terms, or dependent on available appropriations and project scope.
Eligibility is listed broadly as "Others," with a reference to an additional eligibility text field for clarification. In practice, that phrasing usually signals that eligibility may be restricted to certain organization types, existing awardees, or specific entities named or defined in the full notice (for example, particular non-profits, professional organizations, academic institutions, or organizations already engaged in related CDC-supported laboratory quality initiatives). Because this is explicitly labeled as a continuation, it often implies that applicants may need to be current recipients or otherwise meet continuation requirements, though the exact constraint would be confirmed in the full eligibility language.
Overall, the grant opportunity is centered on improving pre-analytical laboratory quality in emergency care by identifying, assessing, and promoting best practices that reduce hemolysis in specimens. The expected outputs would commonly include evidence-based practice evaluations, implementation guidance for ED and laboratory workflows, and recommendations aimed at reducing redraws and improving turnaround time and clinical decision-making, especially in high-pressure ED environments where specimen handling issues are common.
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The opportunity is titled "Reduction of Hemolysis in Specimens from Patients in Emergency Departments: Evaluation of Laboratory Medicine Best Practices and Recommendations."
What is the main purpose of this cooperative agreement?
The purpose is to support work that lowers hemolysis rates in blood specimens collected from patients in emergency departments (EDs) by evaluating laboratory medicine best practices and translating findings into practical, adoptable recommendations for ED settings.
What problem is this opportunity trying to address?
It targets hemolysis, which is the rupture of red blood cells during or after collection. Hemolysis can compromise lab results, lead to specimen rejection, require redraws, cause delays in care, and increase costs.
Why is reducing hemolysis in ED blood specimens important?
Reducing hemolysis improves specimen quality and the reliability of test results. It can also reduce redraws and delays, supporting faster clinical decision-making in high-pressure ED environments.
Who is issuing this funding opportunity?
The opportunity is issued by the U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC).
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is CDC RFA OE15 150302CONT16.
What type of funding instrument is being used?
This opportunity uses a cooperative agreement.
What does it mean that this is a cooperative agreement?
A cooperative agreement generally means CDC is expected to have substantial involvement in the funded activities, rather than serving only as a pass-through funder.
Is this a new opportunity or a continuation?
It is categorized as a continuation opportunity.
What does "continuation opportunity" imply for applicants?
Because it is labeled as a continuation, it often implies applicants may need to be current recipients or otherwise meet continuation requirements. The exact constraint would be confirmed in the full eligibility language referenced by the notice.
What is the activity category for this opportunity?
The activity category is health.
What is the CFDA number associated with this opportunity?
The CFDA number is 93.064, which corresponds to CDC public health-related assistance programs.
When was the announcement posted?
The source data indicates the announcement was created and posted on February 17, 2016.
What is the application closing date?
The application closing date is April 15, 2016. The original and current closing dates are the same in the source data.
What is the award ceiling for this opportunity?
The listing notes an award ceiling of 0.
Does an award ceiling of 0 mean there is no funding available?
Not necessarily. In this listing, an award ceiling of 0 typically suggests that the specific funding amount may be defined elsewhere in the full announcement, negotiated under continuation terms, or dependent on available appropriations and project scope.
How many awards does CDC expect to make under this opportunity?
The listing does not specify the expected number of awards. This can indicate the number of awards may be defined elsewhere in the full announcement or depend on continuation terms, funding availability, and project scope.
Who is eligible to apply?
Eligibility is listed broadly as "Others," with a reference to an additional eligibility text field for clarification.
What does eligibility listed as "Others" generally mean?
In practice, "Others" often signals that eligibility may be restricted to certain organization types, existing awardees, or specific entities named or defined in the full notice (for example, particular non-profits, professional organizations, academic institutions, or organizations already engaged in related CDC-supported laboratory quality initiatives).
Is this opportunity focused specifically on emergency departments?
Yes. The opportunity is centered on specimens collected from patients in emergency departments and on producing recommendations that can be adopted in ED settings.
What kinds of activities are emphasized in this opportunity?
The emphasis is on evaluating laboratory medicine best practices and translating findings into practical recommendations to improve specimen quality and reliability of testing in ED environments.
What kinds of outcomes or deliverables are commonly expected from work like this?
Based on the description, commonly expected outputs would include evidence-based practice evaluations, implementation guidance for ED and laboratory workflows, and recommendations aimed at reducing redraws and improving turnaround time and clinical decision-making.
How does hemolysis affect laboratory testing and patient care?
Hemolysis can compromise lab results, trigger specimen rejection, and lead to redraws. These issues can delay care and increase costs, particularly in ED settings where speed and reliability are critical.
What part of the testing process is this opportunity trying to improve?
It is centered on improving pre-analytical laboratory quality, specifically specimen quality issues that occur during or after blood collection in emergency care contexts.
Browse more opportunities from the same category: Health
Next opportunity: Young Faculty Award
Previous opportunity: Local non-Governmental Partnerships for Sustained Country Leadership in Rwanda under President's Emergency Plan for AIDS Relief (PEPFAR)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA OE15 150302CONT16
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA OE15 150302CONT16) also looked into and applied for these:
| Funding Opportunity |
|---|
| Global Health Security Partnership Engagement: Expanding Efforts and Strategies to Protect and Improve Public Health Globally Apply for CDC RFA GH15 163202CONT16 Funding Number: CDC RFA GH15 163202CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Consortium of National Networks to Impact Populations Experiencing Tobacco-Related and Cancer Health Disparities Apply for CDC RFA DP13 131404CONT16 Funding Number: CDC RFA DP13 131404CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Expanding Partnerships and Disseminating HIV Prevention Materials to Reduce HIV and other STDs among Adolescents through National Non-Governmental Organizations Apply for CDC RFA PS16 1603 Funding Number: CDC RFA PS16 1603 Agency: HHS-CDC-NCHHSTP Category: Health Funding Amount: $400,000 |
| Provider Education and Public Awareness about Primary Immunodeficiency Disease Apply for CDC RFA OE12 120305CONT16 Funding Number: CDC RFA OE12 120305CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement with the National Center for Disease Control and Public Health (NCDC) of the Republic of Georgia Apply for CDC RFA GH12 1259205CONT16 Funding Number: CDC RFA GH12 1259205CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Protecting and Improving Public Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security Apply for CDC RFA GH15 162702CONT16 Funding Number: CDC RFA GH15 162702CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Rwandan Rural Sanitation Activity (RRSA) Apply for RFA 696 16 000002 Funding Number: RFA 696 16 000002 Agency: USAID-RWA Category: Health Funding Amount: $10,700,000 |
| Sustaining Influenza Surveillance Networks and Response to Seasonal and Pandemic Influenza by National Health Authorities outside the United States Apply for CDC RFA IP13 130404CONT16 Funding Number: CDC RFA IP13 130404CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| NIAID SBIR-Technology Transfer Direct Phase II (R44) Apply for RFA AI 16 009 Funding Number: RFA AI 16 009 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities outside the United States Apply for CDC RFA IP13 130604CONT16 Funding Number: CDC RFA IP13 130604CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Botswana Comprehensive Care and Support for Orphans and Vulnerable Children Apply for RFA 674 16 000004 Funding Number: RFA 674 16 000004 Agency: USAID-SAF Category: Health Funding Amount: $12,300,000 |
| State Oral Disease Prevention Program Apply for CDC RFA DP13 130704CONT16 Funding Number: CDC RFA DP13 130704CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Health Department Demonstration Projects to Reduce HIV Infections and Improve Engagement in HIV Medical Care among Men Who Have Sex with Men (MSM) and Transgender Persons Apply for CDC RFA PS15 150602CONT16 Funding Number: CDC RFA PS15 150602CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Strengthening a Regional Public Health Surveillance, Capacity and Laboratory Network for Central America with the Secretaria General del Sistema de la Integracion Centroamericana (SG-SICA)/Consejo de Ministros de Salud de Centroamerica (COMISCA) Apply for CDC RFA GH15 160702CONT16 Funding Number: CDC RFA GH15 160702CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Institutional Research and Academic Career Development Awards (IRACDA) (K12) Apply for PAR 16 103 Funding Number: PAR 16 103 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIGMS Legacy Community-Wide Scientific Resources (R24) Apply for PAR 16 104 Funding Number: PAR 16 104 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Newborn Screening for Severe Combined Immunodeficiency (SCID) Apply for CDC RFA EH15 150402CONT16 Funding Number: CDC RFA EH15 150402CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Protecting and Improving Public Health Systems Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security Apply for CDC RFA GH14 141803CONT16 Funding Number: CDC RFA GH14 141803CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Prescription Drug Overdose Prevention for States Apply for CDC RFA CE15 150102CONT16 Funding Number: CDC RFA CE15 150102CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Bridges to the Doctorate (R25) Apply for PAR 16 109 Funding Number: PAR 16 109 Agency: HHS-NIH11 Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA OE15 150302CONT16", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.